Physiologically Based Pharmacokinetic Modelling of Cabozantinib to Simulate Enterohepatic Recirculation, Drug–Drug Interaction with Rifampin and Liver Impairment
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Physiologically Based Pharmacokinetic Modelling of Cabozantinib to Simulate Enterohepatic Recirculation, Drug–Drug Interaction with Rifampin and Liver Impairment
Authors
Keywords
-
Journal
Pharmaceutics
Volume 13, Issue 6, Pages 778
Publisher
MDPI AG
Online
2021-05-24
DOI
10.3390/pharmaceutics13060778
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Pharmacokinetics of the CYP3A4 and CYP2B6 Inducer Carbamazepine and Its Drug–Drug Interaction Potential: A Physiologically Based Pharmacokinetic Modeling Approach
- (2021) Laura Maria Fuhr et al. Pharmaceutics
- Objective response and prolonged disease control of advanced adrenocortical carcinoma with cabozantinib
- (2020) Matthias Kroiss et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Cabozantinib as a second-line treatment option in hepatocellular carcinoma
- (2020) Alberto D’Angelo et al. Expert Review of Clinical Pharmacology
- Exposure-response modeling of cabozantinib in patients with renal cell carcinoma: Implications for patient care
- (2020) Daniel Castellano et al. CANCER TREATMENT REVIEWS
- Cabozantinib: A Review in Advanced Hepatocellular Carcinoma
- (2019) Emma D. Deeks Targeted Oncology
- Characterization of Genetic Variation in CYP3A4 on the Metabolism of Cabozantinib in Vitro
- (2019) Qian-meng Lin et al. CHEMICAL RESEARCH IN TOXICOLOGY
- A Physiology-Based Model of Human Bile Acid Metabolism for Predicting Bile Acid Tissue Levels After Drug Administration in Healthy Subjects and BRIC Type 2 Patients
- (2019) Vanessa Baier et al. Frontiers in Physiology
- New Insights About Albumin and Liver Disease
- (2018) Joana R. Carvalho et al. Annals of Hepatology
- A sensitive LC-MS/MS method for simultaneous determination of cabozantinib and its metabolite cabozantinib N -oxide in rat plasma and its application in a pharmacokinetic study
- (2018) Lian-jie Ren et al. BIOMEDICAL CHROMATOGRAPHY
- Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
- (2018) Ghassan K. Abou-Alfa et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cabozantinib: A Multitargeted Oral Tyrosine Kinase Inhibitor
- (2018) Jordan N. Markowitz et al. PHARMACOTHERAPY
- Enterohepatic Circulation Effect in Physiologically Based Pharmacokinetic Models: The Sorafenib Case
- (2017) Roberto Andrea Abbiati et al. INDUSTRIAL & ENGINEERING CHEMISTRY RESEARCH
- Cabozantinib: an Active Novel Multikinase Inhibitor in Renal Cell Carcinoma
- (2017) Nizar M. Tannir et al. Current Oncology Reports
- U.S. Food and Drug Administration Approval: Cabozantinib for the Treatment of Advanced Renal Cell Carcinoma
- (2016) Harpreet Singh et al. CLINICAL CANCER RESEARCH
- Clinical Pharmacokinetics and Pharmacodynamics of Cabozantinib
- (2016) Steven A. Lacy et al. CLINICAL PHARMACOKINETICS
- Effect of Renal and Hepatic Impairment on the Pharmacokinetics of Cabozantinib
- (2016) Linh Nguyen et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Impact of Membrane Drug Transporters on Resistance to Small-Molecule Tyrosine Kinase Inhibitors
- (2016) Claudia Neul et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Population Pharmacokinetic Model of Cabozantinib in Patients with Medullary Thyroid Carcinoma and Its Application to an Exposure-Response Analysis
- (2015) Dale Miles et al. CLINICAL PHARMACOKINETICS
- Albumin in chronic liver disease: structure, functions and therapeutic implications
- (2015) Rosaria Spinella et al. Hepatology International
- Pharmacokinetic (PK) drug interaction studies of cabozantinib: Effect of CYP3A inducer rifampin and inhibitor ketoconazole on cabozantinib plasma PK and effect of cabozantinib on CYP2C8 probe substrate rosiglitazone plasma PK
- (2015) Linh Nguyen et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Cabozantinib in Thyroid Cancer
- (2015) Poupak Fallahi et al. Recent Patents on Anti-Cancer Drug Discovery
- Species differences in drug plasma protein binding
- (2014) Nicola Colclough et al. MedChemComm
- Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview
- (2012) Alfred H. Schinkel et al. ADVANCED DRUG DELIVERY REVIEWS
- A physiologically based pharmacokinetic (PBPK) approach to evaluate pharmacokinetics in patients with cancer
- (2012) Sravanthi Cheeti et al. BIOPHARMACEUTICS & DRUG DISPOSITION
- Activity of XL184 (Cabozantinib), an Oral Tyrosine Kinase Inhibitor, in Patients With Medullary Thyroid Cancer
- (2011) Razelle Kurzrock et al. JOURNAL OF CLINICAL ONCOLOGY
- Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth
- (2011) F. M. Yakes et al. MOLECULAR CANCER THERAPEUTICS
- A Computational Systems Biology Software Platform for Multiscale Modeling and Simulation: Integrating Whole-Body Physiology, Disease Biology, and Molecular Reaction Networks
- (2011) Thomas Eissing Frontiers in Physiology
- A Semi-Mechanistic Model to Predict the Effects of Liver Cirrhosis on Drug Clearance
- (2010) Trevor N. Johnson et al. CLINICAL PHARMACOKINETICS
- Clinical pharmacokinetics of tyrosine kinase inhibitors
- (2009) Nielka P. van Erp et al. CANCER TREATMENT REVIEWS
- A Quantitative Enterohepatic Circulation Model
- (2009) Thorsten Lehr et al. CLINICAL PHARMACOKINETICS
- Physiology-Based Simulations of a Pathological Condition
- (2008) Andrea N Edginton et al. CLINICAL PHARMACOKINETICS
- Hepatic drug transporters and nuclear receptors: Regulation by therapeutic agents
- (2008) Aldo D Mottino et al. WORLD JOURNAL OF GASTROENTEROLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More